Arber Qoku

Keywords lymphoma genomics proteomics tumor microenvironment immune exhaustion multi-omics data integration MYC B cell receptor single cell sequencing protein translation Introduction Diffuse large B cell lymphoma (DLBCL) is a genetically and clinically heterogeneous disease. While about 60–70% of patients with DLCBL can be cured with R-CHOP chemoimmunotherapy, 30–40% relapse or are refractory to treatment.